Literature DB >> 23388830

Central venous catheter-related blood stream infections in patients receiving intravenous iloprost for pulmonary hypertension.

D Sammut1, C A Elliot, D G Kiely, I J Armstrong, L Martin, J Wilkinson, P Sephton, J Jones, N Hamilton, J Hurdman, E McLellan, I Sabroe, R Condliffe.   

Abstract

Catheter-related blood stream infection (CR-BSI) in patients with pulmonary hypertension (PH) receiving intravenous iloprost via an indwelling central line has previously not been fully described. Recent studies have suggested a link between the pH of prostanoid infusions and the rate and nature of CR-BSI. We have investigated CR-BSI in patients receiving intravenous iloprost at our unit. Databases and hospital records were interrogated for all patients receiving intravenous iloprost between September 2007 and June 2012. Fifty-nine patients received intravenous iloprost via an indwelling central catheter with a total of 23,072 treatment days. There were 15 episodes of CR-BSI, identified using a systematic screening protocol, involving 11 patients giving an overall CR-BSI rate of 0.65/1,000 treatment days. CR-BSI rate for Gram-positive organisms was 0.26/1,000 treatment-days and for Gram-negative organisms was 0.39/1,000 treatment-days. The pH of iloprost in typical dosing regimens was comparable to the pH used in standard-diluent treprostinil and dissimilar to alkaline epoprostenol infusions. The proportion of Gram-negative CR-BSI was similar to that reported for standard-diluent treprostinil. CRP was normal on admission in 33 % of cases of confirmed CR-BSI and remained normal in 13 % of cases. CR-BSI rates with intravenous iloprost are comparable to those observed for other prostanoids. The high proportion of Gram-negative organisms observed and the neutral pH of iloprost infusions support the previously hypothesised link between pH and antimicrobial activity. Although usually elevated during a CR-BSI, CRP may be normal in early infection and a normal result cannot completely exclude infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23388830     DOI: 10.1007/s10096-013-1822-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  Micrococcus infection in patients receiving epoprostenol by continuous infusion.

Authors:  R L Yap; L A Mermel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-24       Impact factor: 3.267

2.  Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension.

Authors:  Satoshi Akagi; Hiromi Matsubara; Aiko Ogawa; Yusuke Kawai; Kenichi Hisamatsu; Katsumasa Miyaji; Mitsuru Munemasa; Yoshihisa Fujimoto; Kengo Fukushima Kusano; Tohru Ohe
Journal:  Circ J       Date:  2007-04       Impact factor: 2.993

Review 3.  Primary pulmonary hypertension.

Authors:  L J Rubin
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

4.  Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan.

Authors:  D Zaccardelli; K Phares; R Jeffs; A Doran; M Wade
Journal:  Int J Clin Pract       Date:  2010-06       Impact factor: 2.503

5.  Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-03-02       Impact factor: 17.586

6.  Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost.

Authors:  T W Higenbottam; A Y Butt; A T Dinh-Xaun; M Takao; G Cremona; S Akamine
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

7.  Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension.

Authors:  Ronald J Oudiz; Allison Widlitz; X Joy Beckmann; Daisy Camanga; Jose Alfie; Bruce H Brundage; Robyn J Barst
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

8.  Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension.

Authors:  D Dunbar Ivy; Michelle Calderbank; Brandie D Wagner; Susan Dolan; Ann-Christine Nyquist; Michael Wade; William M Nickels; Aimee K Doran
Journal:  Infect Control Hosp Epidemiol       Date:  2009-09       Impact factor: 3.254

9.  Bloodstream infections in patients given treatment with intravenous prostanoids.

Authors:  Alexander J Kallen; Edith Lederman; Alexandra Balaji; Ingrid Trevino; Emily E Petersen; Rivka Shoulson; Lisa Saiman; Evelyn M Horn; Mardi Gomberg-Maitland; Robyn J Barst; Arjun Srinivasan
Journal:  Infect Control Hosp Epidemiol       Date:  2008-04       Impact factor: 3.254

10.  Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.

Authors:  Lars Knudsen; Alexander Schurawlew; Nils Nickel; Henning Tiede; Hossein A Ghofrani; Heinrike Wilkens; Ralf Ewert; Michael Halank; Hans Klose; Carlos Bäzner; Jürgen Behr; Marius M Hoeper
Journal:  BMC Pulm Med       Date:  2011-12-01       Impact factor: 3.317

View more
  4 in total

1.  Central venous line complications with chronic ambulatory infusion of prostacyclin analogues in pediatric patients with pulmonary arterial hypertension.

Authors:  Courtney R Marr; Julia E McSweeney; Mary P Mullen; Thomas J Kulik
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

2.  Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension.

Authors:  Manuel J Richter; Ralf Ewert; Christian Warnke; Henning Gall; Simon Classen; Friedrich Grimminger; Eckhard Mayer; Werner Seeger; Hossein-Ardeschir Ghofrani
Journal:  Clin Res Cardiol       Date:  2016-09-26       Impact factor: 5.460

3.  Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review.

Authors:  Zhichun Gu; Chi Zhang; Anhua Wei; Min Cui; Jun Pu; Houwen Lin; Xiaoyan Liu
Journal:  Sci Rep       Date:  2017-11-24       Impact factor: 4.379

4.  Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy.

Authors:  Elisa K McCarthy; Michelle T Ogawa; Rachel K Hopper; Jeffrey A Feinstein; Hayley A Gans
Journal:  Pulm Circ       Date:  2018-01-08       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.